Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

HBA

- PMLiVE

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Disruption to uptake of HIV and hepatitis C drugs caused by pandemic

- PMLiVE

Gilead makes a play for novel cancer drug with Tizona deal

Pharma company continues oncology biotech spending spree

- PMLiVE

Gilead and Arcus complete closing of ten-year immunotherapy partnership

Deal emphasises Gilead's focus on immuno-oncology

- PMLiVE

Gilead reports remdesivir cuts risk of death in severe COVID-19 patients

Also reveals new analyses from compassionate use programme

- PMLiVE

UPDATED: Gilead drops remdesivir’s orphan drug designation

Decision comes amid intense public criticism of the regulatory status

- PMLiVE

Gilead halts individual requests for COVID-19 hopeful remdesivir

Will now focus on expanded access programmes and backlog

- PMLiVE

Gilead drug reduces HIV viral reservoir, says researcher

Treatment with drug was associated with longer viral suppression

- PMLiVE

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Takeover is latest in a string of billion-plus deals signed by Gilead

- PMLiVE

Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in US

National Institutes of Health initiates trial of experimental drug

- PMLiVE

China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir

Raises concerns over patent exclusivity in the country

- PMLiVE

FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

KTE-X19 is also under regulatory review with the EMA

- PMLiVE

GSK and Gilead join global efforts to tackle novel coronavirus

Confirmed cases rise to over 17,000 in China

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links